Related by context. All words. (Click for frequent words.) 73 Acute Coronary Syndromes 72 Acute Myocardial Infarction 71 Percutaneous Coronary Intervention 70 Myocardial Infarction 70 acute coronary syndrome 70 Ischemic 69 Acute Ischemic Stroke 69 Ischemic Stroke 68 Infarction 68 Prospective Randomized 68 ST Segment Elevation 68 acute coronary syndromes 67 Stent Thrombosis 67 Thrombolysis 67 Drug Eluting Stents 67 Carotid Stenting 67 Intracerebral Hemorrhage 66 Acute Coronary Syndromes ACS 66 ST Elevation Myocardial 66 Overactive Bladder 66 Diabetic Patients 66 Dual Antiplatelet Therapy 66 Coronary Artery Bypass Graft 66 Renal Cell Carcinoma 66 Venous Thromboembolism 66 Cardiovascular Outcomes 65 Chronic Heart Failure 65 unstable angina UA 65 acute myocardial infarction AMI 65 Risk Stratification 65 Unstable Angina 65 STRIDE PD 65 Diabetic Nephropathy 65 undergoing Percutaneous Coronary 65 Severe Sepsis 65 Acute Decompensated Heart Failure 65 Patient Outcomes 65 Myocardial Ischemia 65 Subgroup Analysis 65 Pulmonary Arterial Hypertension 65 Chronic Myeloid Leukemia 65 Aortic Stenosis 65 Cardiovascular Events 64 PICSO ® 64 Ventricular Tachycardia 64 Occlusive Disease 64 Combination Treatment 64 Acute Myocardial 64 Unstable angina 64 infarction NSTEMI 64 Heart Failure Patients 64 Elderly Patients 64 ischemic complications 64 Recurrent Stroke 64 UA NSTEMI 64 Septic Shock 64 Patients Undergoing 64 Adjunctive 64 Pivotal Trial 64 Intracranial 64 Thrombotic 64 tumor lysis syndrome 64 Ranolazine 64 Stenting 64 Anticoagulants 63 Benign Prostatic Hyperplasia 63 Nesiritide 63 Congestive Heart Failure 63 Relapsed Multiple Myeloma 63 Meets Primary Endpoint 63 Oral Fingolimod 63 Hypotension 63 Clinical Trial Results 63 Myelodysplastic Syndromes 63 Ischemia 63 Demonstrates Positive 63 Relapsing Remitting Multiple Sclerosis 63 Radiofrequency Ablation 63 Liver Failure 63 Postmenopausal Women 63 Randomized Evaluation 63 Allergic Rhinitis 63 ARIXTRA 63 Pooled Analysis 63 Atherothrombosis 63 Coronary Artery 63 Randomized Controlled Trials 63 angina pectoris 63 Increased Mortality 63 Statin Therapy 63 Disease Progression 63 Relapsing Multiple Sclerosis 62 Randomized Study 62 Rheumatoid Arthritis Patients 62 Thromboembolism 62 Phase IIb Trial 62 AA Amyloidosis 62 Abciximab 62 unstable angina pectoris 62 Diabetes Mellitus 62 Chronic Constipation 62 antiarrhythmic drug 62 Anticoagulation 62 Clinical Outcome 62 failure ADHF 62 Surgical Treatment 62 Dyslipidemia 62 Cardiogenic Shock 62 acute coronary syndromes ACS 62 Newly Diagnosed Multiple Myeloma 62 Left Ventricular Dysfunction 62 Patients Treated With 62 Acute Heart Failure 62 Bare Metal Stents 62 patients undergoing percutaneous 62 Chronic Renal Failure 62 Platelet Inhibition 62 NATRECOR R 62 Diabetic Neuropathic Pain 62 Decompensated Heart Failure 62 Bivalirudin 62 infarction STEMI 62 Afib 62 arterial thrombosis 62 atherothrombotic disease 62 Left Ventricular 62 Sudden Cardiac Death 62 Arrhythmias 62 Aliskiren 62 Controlled Trial 61 Breast Cancer Recurrence 61 ST elevation myocardial 61 Val HeFT 61 Perindopril 61 Carotid 61 Severe Asthma 61 Cardiovascular Risk 61 Catheter Ablation 61 Plaque Psoriasis 61 thromboembolic 61 Patients Receiving 61 Hypertensive Patients 61 Chronic Sinusitis 61 Bare Metal Stent 61 Antiplatelet Therapy 61 Mitral Regurgitation 61 Drug Eluting Stent 61 NYHA Class II 61 Peripheral Artery Disease 61 Carotid Artery Stenting 61 HeFH 61 Long Term Efficacy 61 Fungal Infections 61 Myocardial Infarction Study 61 stable angina 61 primary percutaneous coronary 61 Coronary Artery Disease 61 Clopidogrel 61 tirofiban 61 Hepatocellular Carcinoma 61 Fracture Risk 61 Solid Tumors 61 Antitumor Activity 61 Insulin Therapy 61 antithrombotics 61 Cardiac Resynchronization Therapy 61 postoperative atrial fibrillation 61 Well Tolerated 61 rFVIIa 61 Treating Chronic 61 Antihypertensive 61 JAK Inhibitor 61 Phase III Clinical Trial 61 Post Operative 61 Invasive Breast Cancer 61 Coronary Angiography 61 segment elevation myocardial 61 Major Depressive Disorder 61 coronary revascularization 61 Valsartan 61 Dose Escalation 61 Bosutinib 61 acute myocardial infarction 61 Monotherapy 61 myocardial infarction 61 complement inhibitor eculizumab 61 Cardiotoxicity 61 Restenosis 61 Resistant Hypertension 61 invasive aspergillosis 61 cardiogenic shock 61 Lung Cancer Patients 61 systolic hypertension 61 Angiographic 61 Diastolic Heart Failure 60 riociguat 60 ACE Inhibitors 60 Atrial Fibrillation AF 60 APPRAISE 60 Implantable Cardioverter Defibrillators 60 Critical Limb Ischemia CLI 60 Phase 2b Clinical Trial 60 First Patient Enrolled 60 ischemic cardiomyopathy 60 NIDDM 60 antithrombotic therapies 60 recurrent glioblastoma multiforme 60 relapsing multiple sclerosis 60 Pioglitazone 60 Complicated Skin 60 Obese Patients 60 VIIBRYD 60 TAXUS Stent 60 IIIa inhibitor 60 Malignant Glioma 60 Pivotal Phase 60 chronic thromboembolic pulmonary 60 Gastric Cancer 60 Novel Oral 60 Breaking Clinical Trials 60 Diabetic Macular Edema 60 ATACAND 60 Randomized Phase 60 atherothrombotic events 60 Bucindolol 60 Hip Fractures 60 Clinical Efficacy 60 multivessel disease 60 dual endothelin receptor antagonist 60 Cognitive Impairment 60 Is Well Tolerated 60 thrombus aspiration 60 Randomized Double Blind Placebo 60 Randomized Phase II 60 Multicenter Study 60 Advanced Melanoma 60 LV dysfunction 60 Aortic Dissection 60 Anticoagulant 60 Renal Artery 60 Artery Disease 60 Statistically Significant 60 terlipressin 60 NATRECOR ® 60 Angiox ® 60 Coronary Artery Bypass Grafting 60 Critical Limb Ischemia 60 Treatment Outcome 60 Fondaparinux 60 silent ischemia 60 Combo Therapy 60 Valve Replacement 60 Cypher Stent 60 CT Angiography 60 Tiotropium 60 Non Alcoholic Fatty 60 Pivotal Phase III 60 Endometrial Cancer 60 coronary intervention 60 Prolongs Survival 60 Obstructive Sleep Apnea 60 Phase IIIb 60 Adjuvant Chemotherapy 60 Rheumatoid Arthritis RA 60 ARCOXIA 60 Progressive Multifocal Leukoencephalopathy 60 Erythropoietic therapies may 60 periprocedural 60 Events MACE 60 Systemic Lupus Erythematosus SLE 60 Trandolapril 60 Microalbuminuria 60 Pulmonary Arterial Hypertension PAH 60 myocardial infarction ventricular fibrillation 60 Premenopausal Women 60 Nymox NX 60 Natalizumab 60 CCX# B 60 icatibant 60 Prophylactic Treatment 60 Cholesterol Lowering Drug 60 Acute Renal Failure 60 Clinical Trial Evaluating 60 decompensated heart failure 60 Adjuvant Treatment 60 Tyrosine Kinase Inhibitor 60 Aneurysm Repair 60 Investigational Agent 60 Multicenter Phase 60 Adjuvant Therapy 60 Multicenter Randomized 60 thrombotic events 60 Subarachnoid hemorrhage 60 Asymptomatic 60 Clinical Trial Data 60 MERLIN TIMI 59 Hepatocellular Carcinoma HCC 59 Late Breaker 59 Cardiac Resynchronization 59 variceal bleeding 59 Bipolar Depression 59 Nebulized 59 Knee Osteoarthritis 59 Novel Antibiotic 59 Neovascular Age Related Macular 59 JAK2 Inhibitor 59 Study Evaluating 59 Advanced Renal Cell 59 PEGylated interferon beta 1a 59 ExTRACT TIMI 59 Renal Function 59 atherothrombotic 59 Differential Diagnosis 59 Metabolic Disorder 59 stable angina pectoris 59 Ambulatory Blood Pressure 59 Hyperkalemia 59 Thrombin Receptor Antagonist 59 Angioedema 59 Sapacitabine 59 Phase 2b Study 59 Nocturia 59 symptomatic intracranial 59 REACH Registry 59 Urinary Incontinence 59 HoFH 59 Rheumatoid Arthritis 59 NSTEMI 59 Neoadjuvant 59 ASTEROID 59 NAVISTAR R 59 Drug Eluting 59 XIENCE V PROMUS Stent 59 Tolvaptan 59 Insulin Resistance 59 Seasonal Allergic Rhinitis 59 invasive candidiasis 59 Valvular 59 Malignant Melanoma 59 Psychiatric Disorders 59 Coronary artery bypass grafting 59 Systemic Sclerosis 59 Venous Thrombosis 59 Embolization 59 Castration Resistant Prostate Cancer 59 Major Adverse Cardiac 59 CABG Surgery 59 Cutaneous T 59 Carotid Endarterectomy 59 Prospective Multicenter 59 Prehypertension 59 Phase Ib Clinical Trial 59 antithrombotic therapy 59 Insulin Sensitivity 59 Phase IIb Clinical Trial 59 Polyneuropathy 59 Treated Patients 59 Diabetic Neuropathy 59 Reduces Mortality 59 Inflammatory Markers 59 T2DM 59 Improves Outcomes 59 MADIT II 59 Tigecycline 59 repeat revascularization 59 Esophagitis 59 failure NYHA 59 patients undergoing CABG 59 Atypical Hemolytic Uremic Syndrome 59 Community Acquired Pneumonia 59 II Clinical Trial 59 antiplatelet medications 59 Eluting Stent 59 See CLINICAL PHARMACOLOGY 59 rheumatoid arthritis osteoarthritis ankylosing 59 Myelofibrosis 59 ENDEAVOR IV 59 Lupus Nephritis 59 Myelodysplastic Syndrome 59 Acute Myocardial Infarction AMI 59 Percutaneous Tibial Nerve Stimulation 59 fibromyalgia syndrome 59 retinal vein occlusion 59 Aggressive Reduction 59 postoperative AF 59 Secondary Hyperparathyroidism 59 Hyperlipidemia 59 Iron Overload 59 Reduce Cardiovascular 59 Renal dysfunction 59 Cholesterol Levels SPARCL 59 MEND CABG 59 hypercholesterolemia 59 ACUITY trial 59 anterior uveitis 59 Hypercholesterolemia 59 myocardial infarction MI 59 Aortic Valve 59 recurrent ischemia 59 angiotensin converting enzyme inhibitors 59 Candesartan 59 Atrial 59 occlusive disease 59 Low Dose 59 Enoxaparin 59 J Am Coll 59 Neovascular AMD 59 ADHF 59 Autologous Stem Cell Transplantation 59 Drug Prevents 59 Cholesterol Levels 59 heparin induced thrombocytopenia 59 left ventricular dysfunction 59 microvascular disease 59 valvular disease 59 severe hypercholesterolemia 59 Coronary Artery Calcium 59 Newly Diagnosed 59 Lenalidomide 58 Safinamide 58 Multicenter 58 Hospital Acquired Pneumonia 58 RENAL 58 Randomized Clinical Trials 58 Serious Infections 58 Migraine Pain 58 Pelvic Organ Prolapse 58 Hematological 58 Carotid Revascularization Endarterectomy vs. 58 CLARITY TIMI 58 Less Invasive 58 chronic myocardial ischemia 58 ticagrelor 58 venous thromboembolic disease 58 Follicular Lymphoma 58 severe aortic stenosis 58 SYNTAX 58 Blood Pressure Monitoring 58 atherothrombosis 58 gefitinib Iressa 58 Inhaled Corticosteroids 58 ACTEMRA TM 58 Bipolar Mania 58 Stroke Risk 58 Irritable Bowel Syndrome IBS 58 Acute MI 58 Echocardiographic 58 Enzastaurin 58 Valvular Heart Disease 58 antiplatelet agent 58 Neurostimulation 58 Clinically Significant 58 Interventional Procedures 58 macrovascular disease 58 Combination REOLYSIN R 58 Treatment Resistant 58 Beta Blocker 58 recurrent ischemic 58 Hospitalized Patients 58 Kidney Failure 58 Cilostazol 58 Pulmonary Artery 58 Acute Pancreatitis 58 Minimally Invasive Treatment 58 NMIBC 58 myelofibrosis polycythemia vera 58 Intravascular 58 Lung Injury 58 clazosentan 58 Lung Cancer Trial 58 Coronary Revascularization 58 AIM HIGH 58 diabetic nephropathy 58 Peripheral Arterial Disease 58 Refractory Angina 58 paroxysmal atrial fibrillation 58 BENICAR HCT 58 EURIDIS 58 LUMINATE 58 Benign Prostatic Hyperplasia BPH 58 multicenter prospective 58 Investigational Treatment 58 Double Blind Placebo 58 PROMUS TM 58 Cypher Sirolimus 58 Metastatic Colorectal Cancer 58 Edge STudy 58 GISSI HF 58 cardiac resynchronisation therapy 58 prospective multicentre 58 Angina 58 Hepatotoxicity 58 Investigational Drug 58 cerebral vasospasm 58 Acute myocardial infarction 58 catheter occlusion 58 acute myocardial infarction MI 58 ECASS 58 Soft Tissue Sarcoma 58 fosbretabulin 58 STEMI 58 Total Hip Replacement 58 Initiate Phase 58 Phase 2a Trial 58 acute ischemic stroke 58 pericardial effusion 58 CYPHER Stent 58 Myocardial 58 Endarterectomy 58 aldosterone antagonists 58 Coronary Stent 58 Idiopathic Pulmonary Fibrosis 58 Meta Analysis 58 MULTAQ 58 Atrial Fibrillation 58 Vulnerable Plaque 58 Gastrointestinal GI 58 Coronary 58 Heterozygous Familial Hypercholesterolemia 58 thromboembolic events 58 Eculizumab 58 pheochromocytoma 58 Long Lesion 58 Cardiovascular Risk Factors 58 #-# Full Text 58 induce orthostatic hypotension 58 Preterm Delivery 58 Bucindolol Based 58 Kidney Transplant Patients 58 ischemia driven 58 Esophageal 58 Impaired Glucose Tolerance 58 myocardial ischemia 58 Suicidality 58 active ankylosing spondylitis 58 chronic idiopathic thrombocytopenic purpura 58 Asthma COPD 58 Exacerbations 58 undergoing coronary artery 58 Zenvia Phase III 58 arterial thromboembolic events 58 nonrandomized 58 Initiates Phase III 58 Sorafenib 58 Cimzia ® certolizumab pegol 58 Systolic Hypertension 58 unstable angina chest 58 Ambrisentan 58 Antiviral Therapy 58 Neuropathic Pain 58 Deep Venous Thrombosis 58 Chronic Insomnia 58 nicardipine 58 Bloodstream Infections 58 Intravitreal 58 Catheterization 58 pulmonary hypertension PH 58 Refractory Hodgkin Lymphoma 58 Renal Failure 58 Bladder Cancer 58 ZOLINZA 58 Ramipril 58 Neuroprotective Effects 58 Intervention Effectiveness 58 cinacalcet 58 hyperglycaemia 58 LVSD 58 Squamous Cell Carcinoma 58 Therapy Reduces 58 Toxicities 58 Peripheral Vascular Disease 57 Peginterferon Alfa 2a 57 either acutely decompensated 57 Generalized Anxiety Disorder 57 Lipid Lowering Treatment 57 Stenosis 57 Ventilator Associated 57 superficial femoral 57 polyarticular 57 dilated cardiomyopathy DCM 57 Heart Failure 57 MACCE 57 Aggressive Drug Evaluation 57 eptifibatide 57 Hepatic 57 BRIM2 57 Cardiovascular Mortality 57 Pegylated Liposomal Doxorubicin 57 INTEGRILIN R 57 diabetic gastroparesis 57 CoreValve System 57 NICE SUGAR 57 familial amyloidotic polyneuropathy FAP 57 Aortic Valve Replacement 57 Epidermal Growth Factor Receptor 57 Dendritic Cells 57 colorectal liver metastases 57 reinfarction 57 RE LY ® 57 vWD 57 functional mitral regurgitation 57 Previously Treated 57 Patients Suffering 57 Hormone Refractory Prostate Cancer 57 Transcatheter 57 Reperfusion 57 Oral Mucositis 57 bypass graft CABG surgery 57 Drug Shows Promise 57 Nicotine Vaccine 57 Insulin Glargine 57 Sleep Disturbances 57 Thromboembolic 57 Phase IIa Clinical Trial 57 Venous thromboembolism 57 Minimally Invasive Procedure 57 Synta Announces 57 Major Depressive Disorder MDD 57 renal artery stenosis 57 anticoagulant warfarin 57 Receptor Antagonists 57 Peripheral Arterial 57 Dupuytren Contracture 57 Vimpat R 57 Lacosamide 57 prospective multicenter study 57 Atherosclerotic 57 upper gastrointestinal bleeding 57 Mitral Valve Repair 57 metastatic malignant 57 Migraine Headaches 57 Uterine Fibroids 57 Slow Progression 57 Genes Predict 57 intermittent claudication 57 Thrombocytopenia 57 overactive bladder syndrome 57 Fabry Disease 57 unfractionated heparin UFH 57 SORT OUT III 57 TAXUS TM 57 unstable angina 57 Therapeutic Targets 57 Restless Legs Syndrome RLS 57 Recurrent Glioblastoma 57 fibrinolytic therapy 57 thromboembolism 57 hyperkalemia 57 renal impairment 57 AFib 57 Osteoarthritis Patients 57 Arch Intern Med 57 atypical Hemolytic Uremic Syndrome 57 Pharmacological 57 Chronic Lymphocytic Leukemia 57 COPERNICUS 57 Nilotinib 57 EXJADE 57 Eltrombopag 57 CIMZIA TM certolizumab pegol 57 Coronary Disease 57 Juvenile Idiopathic Arthritis 57 TRITON TIMI 57 paroxetine Paxil 57 Olmesartan 57 juvenile idiopathic arthritis 57 Pirfenidone 57 candesartan 57 Rilonacept 57 Stent thrombosis 57 antihypertensive agents 57 Treatment Reduces 57 thromboembolic disease 57 infusional 57 Thiazolidinediones 57 Celebrex celecoxib 57 Corneal Transplant 57 Laryngeal Cancer 57 adult chronic ITP 57 See WARNINGS 57 Glatiramer Acetate 57 paclitaxel eluting stents 57 Chronic Bronchitis 57 Breast Cancer Treatment 57 Fingolimod 57 Exacerbation 57 Peptic Ulcer 57 cytopenias 57 Chronic Hepatitis B 57 Treatment Naive Patients 57 ANN INTERN MED 57 Subtypes 57 Methylnaltrexone 57 tolvaptan 57 Atopic Dermatitis 57 Placebo Controlled Trial 57 IPAH 57 intracerebral hemorrhage 57 Reduced Risk 57 ACE Inhibitor 57 Renal Cell Carcinoma RCC 57 Myelodysplastic Syndrome MDS 57 antiphospholipid syndrome 57 beta blocker therapy 57 Anxiety Depression 57 Controlled Study 57 multicenter randomized controlled 57 ximelagatran 57 Bone Mineral Density 57 Genetic Variations 57 Renal Cancer 57 candesartan cilexetil 57 Irbesartan 57 Delayed Graft Function 57 Endothelial Dysfunction 57 Pharmacokinetic Study 57 Prostate Cancer Treatment 57 Ischaemic 57 dyslipidemia hypertension diabetes 57 TM Drug Eluting 57 VADT 57 R lenalidomide 57 Demonstrates Significant 57 Contrast Agent 57 Blood Clots 57 NeuroStar TMS Therapy 57 cerebrovascular events 57 Blood Pressure Drug 57 relapsing remitting MS RRMS 57 treatment naive genotype 57 Percutaneous Transluminal Coronary Angioplasty 57 ONTARGET 57 NSTE ACS 57 patientswith 57 aortic valve stenosis 57 Randomized Double Blind 57 sirolimus eluting stents 57 DU #b 57 Drug Eluting Stent System 57 nonfatal myocardial infarction MI 57 Angiox R 57 Microwave Ablation System 57 Alteplase 57 revascularisation 57 myocardial infarction stroke 57 Rheumatoid Arthritis Drug 57 phase IIb clinical 57 Enzyme Replacement Therapy 57 STENT 57 Prediabetes 57 angiotensin II receptor blockers 57 PREVENT IV 57 Carcinoma 57 Investigational Compound 57 Generalised Anxiety Disorder 57 Enlarged Prostate 57 revascularizations 57 Implantable Device 57 osteoarthritis rheumatoid arthritis 57 percutaneous transluminal coronary angioplasty 57 Total Knee Replacement 57 XIENCE V demonstrated 57 PRADAXA 57 Skeletal Muscle 57 substudy 57 Glucose Monitoring 57 Antiplatelet 57 VAPRISOL 57 Etanercept 57 External Defibrillators 56 recurrent DVT 56 carotid stenting 56 Clinical Outcomes Utilizing Revascularization 56 PRoFESS 56 Initiates Enrollment 56 TMS Therapy 56 oral anticoagulant 56 Stress Incontinence 56 Hsp# Inhibitor 56 Multicenter Trial 56 macrovascular 56 Phase 1b Clinical Trial 56 Reperfusion Injury 56 phase IIb trial 56 Statin Use 56 venous thromboembolic events 56 Ankylosing Spondylitis 56 risk stratification 56 Chronic HCV 56 Novel Therapies 56 PLX STROKE targeting 56 Albuminuria 56 Proteinuria 56 oral antiplatelet therapy 56 Antiviral Activity 56 Dialysis Outcomes 56 RE LY 56 hypercholesterolaemia 56 Dalbavancin 56 Circulatory Support 56 thrombolytic therapy 56 Adverse Event 56 saphenous vein graft 56 Romiplostim 56 BERKELEY CA UroToday.com 56 biliary tract cancer 56 relapsed refractory multiple myeloma 56 assessing T DM1 56 Golimumab 56 Dose Ranging Study 56 subclinical hypothyroidism 56 multicentre randomized 56 Mild Cognitive Impairment 56 Arterial Disease 56 renal artery stenting 56 Postmarketing 56 Ventricular Assist Devices 56 Aurora Kinase 56 CHAMPION PCI 56 Insulin Delivery 56 INVEGA ® 56 onset atrial fibrillation 56 Treat Heart Failure 56 Ovarian Cancer Patients 56 bivalirudin alone 56 aripiprazole Abilify 56 Beta Blockers 56 antiplatelet agents 56 Rivaroxaban 56 Schizophrenia Treatment 56 CYPHER R Sirolimus Eluting 56 Stable Angina 56 perioperative complications 56 metastatic neuroendocrine tumors 56 Comorbidities 56 nonfatal MI 56 severe exacerbations 56 CABG 56 CIMZIA TM 56 Degarelix 56 interstitial pneumonia 56 Hepatic Encephalopathy 56 acute PAO 56 PEGINTRON TM 56 Patency 56 Clinical Practice Guideline 56 drug eluting stent implantation 56 PFO closure 56 CRT ICD 56 Eluting Coronary Stent System 56 Ulcerative Colitis 56 AFREZZA TM 56 DES implantation 56 myelodysplastic myeloproliferative diseases 56 Granted Orphan Drug 56 nephrotoxicity 56 Cardiovascular Disease Risk 56 Idiopathic 56 Claudication 56 Fibrates 56 Telmisartan 56 Stem Cell Treatment 56 CIMZIA ™ 56 Targeted Therapy 56 Chronic Migraine 56 TAXUS Express2 56 bronchial hyperresponsiveness 56 Uterine Fibroid Embolization 56 aspirin clopidogrel 56 First Patient Dosed 56 Shows Efficacy 56 Iron Deficiency 56 Replacement Therapy 56 Systemic Lupus Erythematosus 56 Outpatient Setting 56 extrapyramidal symptoms 56 undergoing percutaneous coronary 56 Orthostatic Hypotension 56 venlafaxine Effexor 56 ACTOS ® 56 Dilated Cardiomyopathy 56 Improved Survival 56 PRECISE 56 Cardiometabolic 56 toenail onychomycosis 56 HCV SPRINT 56 Blood Cancers 56 Drug eluting stent 56 psoriatic arthritis PsA 56 Interferon beta 1a 56 thromboprophylaxis 56 DPNP 56 Novel Mechanism 56 Hemophilia B 56 artery stenosis 56 Randomized Comparison 56 HuMax EGFr 56 PROCRIT R 56 subanalysis 56 MIST II 56 Thrombolytic Therapy 56 Cardiac Arrest Patients 56 Tyrosine Kinase Inhibitors 56 REALITY Trial 56 Thyroid Hormone 56 Boosts Survival 56 Fibromyalgia Syndrome 56 Cardiac Ablation 56 computed tomography angiography 56 receptor tyrosine kinase inhibitor 56 refractory angina 56 non valvular atrial 56 Prognostic Significance 56 Initiated Phase 56 Cardiac Failure 56 stratifying patients 56 SYNTAX trial 56 EchoCRT 56 TNF antagonist 56 Demonstrates Efficacy 56 peripheral arterial occlusive disease 56 Bone Fractures 56 variant angina 56 MADIT 56 Dasatinib 56 Helicobacter pylori eradication 56 occlusion CRVO 56 Mg Usa 56 Biphasic 56 hyperphenylalaninemia HPA due 56 gastrointestinal GI motility disorders 56 Therapy Evaluation 56 mild renal insufficiency 56 comorbid conditions 56 metastatic renal cell carcinoma 56 Parkinson Disease PD 56 thetreatment 56 Drug Candidate 56 Double Blind Randomized 56 Sipuleucel T 56 Randomized Double blind 56 Renal Tumors 56 CYP#A# CYP#D# 56 Interferon Beta 56 APEX AMI trial 56 Serious Adverse Events 56 serum phosphorous 56 Alzheimer Disease AD 56 Node Positive 56 Vascular Disease 56 Antipsychotic 56 Hydroxyurea 56 venous insufficiency 56 Ivabradine 56 deep venous thromboses 56 Hormone Therapy 56 antihypertensives 56 Generalized Anxiety Disorder GAD 56 postoperative delirium 56 ARBITER 6 56 ACOMPLIA R 56 myopathy rhabdomyolysis 56 Coronary Arteries 56 receiving VELCADE 56 Hemodialysis Patients 56 TNF Blockers 56 Temsirolimus 56 Stent Placement 56 resynchronization therapy 56 pulmonary artery hypertension 56 PERSEUS 56 Phase III AFFIRM 56 Lung Function 56 cardiovascular hospitalization 56 Interstitial Cystitis 56 Gestational Diabetes 56 SUTENT ® 56 Cachexia 56 Coronary Stents 56 ThermoDox R 56 Bazedoxifene 56 Autoimmune Disease 56 PAOD 56 Tocilizumab 56 Xelox 56 Complication Rates 56 carotid artery stenting 56 renal denervation 56 tachyarrhythmias 56 alfuzosin 56 Often Misdiagnosed 56 HCV Protease Inhibitor 56 transcranial Doppler ultrasound 56 brivaracetam 56 Endocarditis 56 ezetimibe simvastatin 56 clevidipine 56 Obese Teens 56 Novel Compound